Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis

  • Crit Care Med. 2009 Apr;37(4):1403-7. doi: 10.1097/CCM.0b013e31819c3e22.
Oscar Cirioni  1 ,  Carmela Silvestri ,  Roberto Ghiselli ,  Fiorenza Orlando ,  Alessandra Riva ,  Eleonora Gabrielli ,  Federico Mocchegiani ,  Nancy Cianforlini ,  Maria Michela Cappelletti Trombettoni ,  Vittorio Saba ,  Giorgio Scalise ,  Andrea Giacometti
Affiliations
  • 1. Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy. [email protected]
PMID: 19318826 DOI: 10.1097/CCM.0b013e31819c3e22
Abstract

Objective: To investigate the efficacy of buforin II and rifampin in an experimental rat model of Acinetobacter baumannii sepsis.

Design: Prospective, randomized, controlled animal study.

Setting: Research laboratory in a university hospital.

Subjects: Adult male Wistar rats.

Interventions: The Animals received intraperitoneally 1 mL saline containing 2 x 10 colony forming units of A. baumannii ATCC 19606 (model i) or the multiresistant strain (model ii). Immediately after Bacterial challenge, Animals received intravenously a single dose of isotonic sodium chloride solution (control groups C1 and C2), 1 mg/kg of buforin II, 10 mg/kg of rifampin, and 1 mg/kg of buforin II plus 10 mg/kg of rifampin, respectively.

Measurements and main results: Lethality, Bacterial growth in blood and tissue burden, endotoxin, interleukin-6, and tumor necrosis factor-alpha concentrations in plasma. Buforin II showed good antimicrobial activity and achieved a significant reduction of plasma endotoxin and cytokines concentration when compared with control and rifampin-treated groups. Combination among buforin II proved to be the most effective treatment in reducing all variables measured.

Conclusion: In an experimental model, buforin II and rifampin might have a potential role in the treatment of severe infections due to A. baumannii.

Products